FDA Advisers Vote Today on Grail's Galleri Cancer Test as Stock Surges 35% and Kennedy's Private Support Draws Scrutiny

Since GRAIL shares closed at $108 on Monday, September 21, up 34-35% in a single session, the company has been waiting on today's vote from an FDA advisory panel that could decide whether its Galleri blood test gets full federal approval.

The FDA's Molecular and Clinical Genetics Panel is meeting today, September 23, from 9 a.m. to 6 p.m. ET to review Grail's premarket approval application and vote on a recommendation, according to BigGo Finance. The panel's conclusion is advisory, not binding. The FDA has final say and often, but not always, follows its panels' advice, according to NPR.

Monday's rally traces to FDA briefing documents released ahead of the meeting. Staff reviewers told the panel they have no outstanding questions on Galleri's analytical performance, study design, or primary safety analyses, according to Traders Union and Tikr. Piper Sandler analyst David Westenberg called the release "constructive for Grail" and said he expects a favorable vote. RBC Capital Markets read it similarly, noting the FDA's remaining questions center on labeling rather than core test validity, according to Tikr.

Despite the rally, Wall Street's own numbers show skepticism. Tikr reports 11 analysts covering GRAL stock, split five buys and six holds, with a mean price target of $79 as of September 21, which sits 27% below Monday's $108 close.

What the FDA staff didn't clear

The one question FDA staff explicitly asked the panel to address is whether Galleri's data support calling it an "early detection" test, according to Tikr and Ground News. That question stems from the NHS-Galleri trial, a three-year UK study of roughly 142,000 patients ages 50 to 77, which missed its primary goal of significantly reducing late-stage cancer diagnoses compared to standard screening alone, according to Ground News and the Hindustan Times.

The trial data show a mixed picture. Diagnoses of the 12 deadliest cancers at stages one and two rose 16% in the Galleri group, according to the Hindustan Times. But stage three diagnoses in that group rose 25% while stage four diagnoses fell 14%, a pattern the Hindustan Times argues points to earlier detection even though the trial's headline endpoint failed. Ground News reports the test's positive predictive value was 52%, meaning roughly half of positive results are ultimately confirmed as cancer.

Leading medical associations do not currently recommend for or against multi-cancer blood tests in people without symptoms, according to the Washington Sun. That absence of professional consensus is the strongest case critics have for caution. A test that flags false positives can push patients into invasive, costly follow-up care they wouldn't otherwise need, even though the Hindustan Times notes 85% of follow-up evaluations after a positive Galleri result are non-invasive.

Kennedy's private support and the MAHA Summit

Health Secretary Robert F. Kennedy Jr. privately told aides in a meeting last winter that he wants a federal task force on preventive services to recommend multi-cancer blood tests, according to a former HHS official who was in the meeting and spoke to the Washington Sun. A second former official told the outlet Kennedy repeatedly expressed the same view. Those accounts are unconfirmed by any on-record HHS statement and no investigation or formal proceeding has been announced.

The timing matters because companies that sell these tests are financially entangled with the movement Kennedy leads. Grail and Prenuvo, which sells full-body MRI scans for around $2,500, are sponsors of next week's Make America Healthy Again Summit at the Waldorf Astoria, according to the Washington Sun. Grail CEO Joshua Ofman and Superpower CEO Max Marchione, whose company resells Galleri for $949, are scheduled to speak on panels there alongside Trump administration health officials. Longevity entrepreneur Bryan Johnson, tied to a competing scan sold by Function Health, led by Kennedy's friend Mark Hyman, is also on the agenda.

Congress has already voted to allow Medicare to reimburse FDA-approved multi-cancer detection tests starting in 2028, according to Ground News, which is why full approval carries such financial weight for Grail and its rivals, including Abbott's Cancerguard, which remains on the market without FDA sign-off under separate lab-developed test rules.

No source in this record states how today's panel actually voted. The FDA is not required to act immediately on the recommendation, and no timeline for a final agency decision has been disclosed. Whatever the panel decides, the underlying dispute over whether Galleri's stage-shifting data amounts to genuine early detection, or whether the NHS trial's failed endpoint is disqualifying, remains unresolved and will likely resurface when the FDA issues its final ruling.